Eric Libre, MD
Pulmonary Disease · Annandale, VANPI 1710993001
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $256,215 of the $301,754 with a category attached, or 84.9%. GSK accounts for 70.2% of it on its own, with 37 other manufacturers making up the rest. Among pulmonary disease clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 702 payments — averaging $429.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$212K
- AstraZeneca$79K
- Johnson & Johnson$3K
- Sanofi$966
- Regeneron Healthcare Solutions, Inc.$805
- Amgen$688
- plus $5K from 32 others
What the payments were for
- Consulting fees$15,0195%
- Speaking & faculty fees$256,21585%
- Travel & lodging$11,8984%
- Food & beverage$17,8936%
- Education$7110%
- Gifts$170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 230 | $211,976 |
| AstraZeneca | 192 | $79,107 |
| Johnson & Johnson | 13 | $3,382 |
| Sanofi | 42 | $966 |
| Regeneron Healthcare Solutions, Inc. | 17 | $805 |
| Amgen | 26 | $688 |
| Viiv Healthcare Company | 1 | $600 |
| Boehringer Ingelheim | 27 | $574 |
| Genentech USA, Inc. | 22 | $536 |
| United Therapeutics Corporation | 7 | $331 |
| Inari Medical, Inc. | 2 | $313 |
| Insmed, Inc. | 13 | $281 |
| Electromed, Inc. | 11 | $247 |
| Verona Pharma, Inc. | 8 | $235 |
| Actelion Pharmaceuticals US, Inc. | 12 | $233 |
| Grifols USA, LLC | 9 | $221 |
| Shionogi Inc | 15 | $185 |
| Baxter Healthcare | 5 | $126 |
| Mylan Specialty L.p. | 6 | $113 |
| Mallinckrodt Hospital Products Inc. | 3 | $95 |
| Philips North America LLC | 5 | $90 |
| Novartis | 4 | $75 |
| Circassia Inc. | 4 | $62 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $61 |
| Pfizer | 4 | $60 |
| Teva Pharmaceuticals USA, Inc. | 3 | $55 |
| Gilead | 3 | $49 |
| Vapotherm Inc | 2 | $41 |
| Bayer | 2 | $39 |
| Shire North American Group Inc | 2 | $34 |
| Merck | 2 | $29 |
| E.r. Squibb & Sons, L.L.C. | 2 | $27 |
| Pulmonx Corporation | 1 | $27 |
| Optinose US, Inc. | 1 | $23 |
| Phadia US Inc. | 1 | $19 |
| Sanofi Pasteur Inc. | 1 | $19 |
| Harmony Biosciences LLC | 1 | $18 |
| Advanced Respiratory, Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$97,944
- NUCALA$66,107
- FASENRA$43,409
- AREXVY$21,044
- AIRSUPRA$15,841
- TEZSPIRE$14,941
- ANORO$4,762
- XARELTO$3,138
- FLOWTRIEVER CATHETER, S$313
- CT THROMBECTOMY SYSTEM KIT$313
- BREZTRI$247
- DUPIXENT$245
- ANORO ELLIPTA$221
- TYVASO$174
- Ohtuvayre$130
- SYMBICORT$122
How this compares
$301,754 in reported general payments places this provider in the 95th percentile of 317 pulmonary disease providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 90 | $1,068,677 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 211 | $304,895 |
| Spiriva RespimatTiotropium Bromide | 132 | $130,197 |
| Fasenra PenBenralizumab | 22 | $126,422 |
| Dupixent PenDupilumab | 31 | $119,726 |
| FasenraBenralizumab | 20 | $114,998 |
| Breo ElliptaFluticasone/Vilanterol | 122 | $84,528 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 89 | $79,079 |
| XareltoRivaroxaban | 62 | $72,486 |
| Dupixent SyringeDupilumab | 18 | $65,388 |
| EliquisApixaban | 39 | $45,402 |
| Incruse ElliptaUmeclidinium Bromide | 54 | $42,499 |
| Arnuity ElliptaFluticasone Furoate | 97 | $41,475 |
| Qvar RedihalerBeclomethasone Dipropionate | 90 | $40,895 |
| SymbicortBudesonide/Formoterol Fumarate | 82 | $32,936 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat | $574 | $1,198,874222 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta, Anoro Ellipta | $211,976 | $502,206515 claims |
| AstraZenecaFasenra, Breztri Aerosphere, Symbicort, Pulmicort Flexhaler | $79,107 | $237,170216 claims |
| Johnson & JohnsonXarelto | $3,382 | $72,48662 claims |
| PfizerEliquis | $60 | $45,40239 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $55 | $40,89590 claims |
| MerckDulera | $29 | $4,85011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 317 pulmonary disease providers in Virginia.
Other pulmonary disease in Annandale
- Vishal MungalAnnandale$44K
- Steven NathanFalls Church$1.5M
- Omar MinaiHopewell$1.3M
- Rabih HalabiFalls Church$604K
- Sujoy GillRichmond$296K
- Imre NothCharlottesville$256K
- Carlos SilvaChesapeake$245K
- Vijay SubramaniamWilliamsburg$228K
- Ellen VolkerCharlottesville$177K
- Himanshu DesaiChesapeake$174K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.